DAVIS STEPHEN
Known title: CEOCIK: 0001131146
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Transaction History
| ACAD | ▼ Sell | Open Market | 31,747 | $485K | 8/19/2024 | View on chart |
| ACAD | ▲ Buy | Grant | 17,333 | $0 | 8/16/2024 | View on chart |
| ACAD | ▲ Buy | Grant | 44,782 | $0 | 8/16/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 11,427 | $194K | 5/2/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 22,391 | — | 5/1/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 8,858 | $158K | 4/8/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 17,716 | $317K | 4/8/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 17,333 | — | 4/5/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 34,666 | — | 4/5/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 17,714 | $317K | 3/27/2024 | View on chart |
| ACAD | ▲ Buy | Grant | 34,666 | $0 | 3/25/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 5,577 | $138K | 2/26/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 10,946 | — | 2/23/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,732 | $112K | 1/8/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,528 | — | 1/6/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 51,563 | $1.1M | 10/6/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 103,999 | — | 10/5/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 100,000 | $2.1M | 7/14/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 100,000 | $3.0M | 7/14/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 55,104 | $1.4M | 7/12/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 16,498 | $412K | 7/11/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 7,806 | $165K | 5/1/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 15,625 | $0 | 4/29/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 8,582 | $156K | 4/6/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 17,333 | — | 4/5/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,851 | $72K | 2/24/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 10,945 | — | 2/23/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,904 | $67K | 1/9/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,528 | — | 1/6/2023 | View on chart |
| HRTX | ▲ Buy | Grant | 38,580 | $0 | 12/16/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,938 | — | 10/15/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,804 | $44K | 10/15/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 5,483 | $100K | 5/2/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 15,625 | — | 4/29/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 10,945 | $0 | 2/23/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,928 | $93K | 2/23/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,527 | — | 1/6/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,718 | $86K | 1/6/2022 | View on chart |
| HRTX | ▲ Buy | Grant | 10,452 | $0 | 12/22/2021 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,963 | $52K | 10/18/2021 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,938 | — | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates
RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.